Jennifer Rivers, APRN
Nurse Practitioner · Hartford, CTNPI 1205816311
Payments from drug & device makers
Across 43 payments — averaging $33.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$237
- Otsuka America Pharmaceutical, Inc.$145
- Calliditas Therapeutics US Inc.$130
- Medtronic$122
- Mallinckrodt Hospital Products Inc.$107
- AstraZeneca$95
- plus $609 from 17 others
What the payments were for
- Food & beverage$1,42599%
- Education$201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 2 | $237 |
| Otsuka America Pharmaceutical, Inc. | 4 | $145 |
| Calliditas Therapeutics US Inc. | 2 | $130 |
| Medtronic | 1 | $122 |
| Mallinckrodt Hospital Products Inc. | 3 | $107 |
| AstraZeneca(2 entities) | 4 | $95 |
| Amgen | 3 | $82 |
| Boehringer Ingelheim | 3 | $77 |
| Novartis | 2 | $76 |
| Alnylam Pharmaceuticals Inc. | 3 | $66 |
| Novo Nordisk | 2 | $51 |
| Pfizer | 2 | $47 |
| Bayer | 1 | $31 |
| Aurinia Pharma U.S., Inc. | 1 | $24 |
| Scpharmaceuticals Inc. | 1 | $24 |
| Apellis Pharmaceuticals, Inc. | 1 | $23 |
| Akebia Therapeutics Inc | 1 | $21 |
| Ardelyx, Inc. | 1 | $20 |
| OPKO Pharmaceuticals, LLC | 1 | $20 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $17 |
| Veloxis Pharmaceuticals, Inc. | 1 | $15 |
| Genentech USA, Inc. | 2 | $14 |
| Travere Therapeutics, Inc. | 1 | $0 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Embotrap$140
- ELLIPSYS VASCULAR ACCESS SYSTEM$122
- TARPEYO$101
How this compares
$1,445 in reported general payments places this provider in the 85th percentile of 1,162 nurse practitioner providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 156 | $136,950 |
| JardianceEmpagliflozin | 48 | $45,322 |
| LokelmaSodium Zirconium Cyclosilicate | 30 | $25,090 |
| RayaldeeCalcifediol | 20 | $24,796 |
| VeltassaPatiromer Calcium Sorbitex | 17 | $18,036 |
| Cinacalcet Hcl | 18 | $16,181 |
| Potassium Citrate ErPotassium Citrate | 27 | $4,160 |
| Eplerenone | 21 | $2,739 |
| Clonidine | 17 | $2,544 |
| Losartan Potassium | 227 | $2,377 |
| Calcitriol | 135 | $2,293 |
| Nifedipine ErNifedipine | 53 | $1,858 |
| Amlodipine Besylate | 240 | $1,821 |
| Spironolactone | 95 | $1,495 |
| Lisinopril | 139 | $1,043 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $95 | $162,040186 claims |
| Boehringer IngelheimJardiance | $77 | $45,32248 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $20 | $24,79620 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,162 nurse practitioner providers in Connecticut.
Other nurse practitioner in Hartford
- Patricia BozemanHartford$11K
- Annette EpplerHartford$10K
- Angel RentasHartford$8K
- Kristina AmatoHartford$5K
- Angela BoisseauHartford$5K
- John Martin-BeaulieuHartford$5K
- Sandra PalmerHartford$4K
- Lindita VincaCheshire$427K
- Catherine MilnePlymouth$361K
- Michele NovellaDanbury$331K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.